Mikael Dolsten
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial. Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Pfizer Declares 352nd Straight Dividend, Holds Steady Amid Vaccine Selloff. Pfizer announced its 352nd consecutive quarterly dividend, keeping a yield of about 5.4%. The company’s share price has stayed flat even as other vaccine makers like Novavax and Moderna fell. A new approval for the drug Tukysa could alter the company’s outlook, and analysts are watching the upcoming Q3 2026 earnings report for more detail.
Transaction History
| A | ▼ Sell | Open Market | 634 | $96K | 9/4/2026 | View on chart |
| RCKT | ▲ Buy | Grant | 22,862 | $0 | 6/18/2026 | View on chart |
| A | ▼ Sell | Open Market | 1,600 | $217K | 5/29/2026 | View on chart |
| A | ▲ Buy | Grant | 2,158 | $241K | 3/19/2026 | View on chart |
| A | ▼ Sell | Open Market | 2,600 | $390K | 12/1/2025 | View on chart |
| RCKT | ▲ Buy | Grant | 30,000 | $0 | 6/18/2025 | View on chart |
| A | ▲ Buy | Grant | 1,819 | $220K | 3/14/2025 | View on chart |
| RCKT | ▼ Sell | Other | 14,220 | $0 | 3/5/2025 | View on chart |
| A | ▲ Buy | Grant | 1,678 | $247K | 3/15/2024 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 21,437 | $580K | 2/28/2024 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 24,822 | $689K | 2/23/2024 | View on chart |
| A | ▲ Buy | Grant | 1,658 | $227K | 3/16/2023 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 37,078 | $1.5M | 2/25/2023 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 32,592 | $1.4M | 2/22/2023 | View on chart |
| PFE | ▲ Buy | Option Exercise | 50,938 | $1.5M | 11/7/2022 | View on chart |
| PFE | ▲ Buy | Option Exercise | 28,170 | $1.1M | 11/7/2022 | View on chart |
| PFE | ▼ Sell | Open Market | 200 | $10K | 5/11/2022 | View on chart |
| PFE | ▼ Sell | Open Market | 2,358 | $116K | 5/11/2022 | View on chart |
| PFE | ▼ Sell | Open Market | 2,891 | $143K | 5/11/2022 | View on chart |
| PFE | ▼ Sell | Open Market | 7,876 | $389K | 5/11/2022 | View on chart |
| PFE | ▼ Sell | Open Market | 18,562 | $915K | 5/11/2022 | View on chart |
| PFE | ▼ Sell | Open Market | 32,015 | $1.6M | 5/11/2022 | View on chart |
| A | ▲ Buy | Grant | 1,785 | $244K | 3/17/2022 | View on chart |
| PFE | ▲ Buy | Option Exercise | 62,022 | $1.7M | 3/3/2022 | View on chart |
| PFE | ▲ Buy | Option Exercise | 40,438 | $1.6M | 3/3/2022 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 29,744 | $1.4M | 2/26/2022 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 29,767 | $1.4M | 2/23/2022 | View on chart |
| PFE | ▲ Buy | Option Exercise | 71,187 | $2.1M | 12/17/2021 | View on chart |
| PFE | ▲ Buy | Option Exercise | 76,135 | $1.7M | 11/11/2021 | View on chart |
| PFE | ▲ Buy | Option Exercise | 64,841 | $1.8M | 11/11/2021 | View on chart |
| PFE | ▲ Buy | Option Exercise | 58,572 | $1.5M | 11/11/2021 | View on chart |
| PFE | ▼ Sell | Open Market | 2,124 | $107K | 11/11/2021 | View on chart |
| PFE | ▼ Sell | Open Market | 2,301 | $116K | 11/11/2021 | View on chart |
| PFE | ▼ Sell | Open Market | 3,197 | $161K | 11/11/2021 | View on chart |
| PFE | ▼ Sell | Open Market | 3,396 | $171K | 11/11/2021 | View on chart |
| PFE | ▼ Sell | Open Market | 5,227 | $263K | 11/11/2021 | View on chart |
| PFE | ▼ Sell | Open Market | 6,708 | $338K | 11/11/2021 | View on chart |
| PFE | ▼ Sell | Open Market | 36,711 | $1.8M | 11/11/2021 | View on chart |
| A | ▲ Buy | Grant | 567 | $98K | 9/22/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Agilent to acquire Proscia for up to $270M
Agilent Technologies has agreed to acquire digital pathology specialist Proscia in a deal valued at up to $270 million. The move is designed to strengthen Agilent's position in AI-enabled diagnostics and scientific intelligence. Following the announcement, TD Cowen raised its price target for the stock to $196.
Agilent to acquire Proscia for up to $270M. Agilent Technologies has agreed to acquire digital pathology specialist Proscia in a deal valued at up to $270 million. The move is designed to strengthen Agilent's position in AI-enabled diagnostics and scientific intelligence. Following the announcement, TD Cowen raised its price target for the stock to $196.